NeurologyLive Friday 5 — December 11, 2020

December 11, 2020
NeurologyLive Staff

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending December 11, 2020.

Welcome to NeurologyLive's Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: Insights: Importance of Early Diagnosis of Dravet Syndrome

M. Scott Perry, MD, stresses the importance of an early diagnosis for Dravet syndrome, and what tools are available to help with early diagnosis. (For more on the latest in Dravet, check out our coverage of AES 2020!)

2: NeuroVoices: Christian Meisel, MD, PhD, on Forecasting Seizures

Christian Meisel, MD, PhD, department of neurology, Universitätsmedizin Berlin, and Berlin Institute of Health, discussed the landscape for devices that forecast seizures, including the use of multi-modal wristband sensors.

3: Ublituximab Meets Primary End Point in Relapsing MS Studies

Further results of the 2 phase 3 studies, ULTIMATE I (NCT03277261) and ULTIMATE II (NCT03277248), are expected to be completed and presented in detail in first half of 2021, with a BLA submission to follow.

4: Acute Migraine Treatment: Pain Freedom and Guidelines

Amaal J. Starling, MD, considers the importance of the pain freedom end point and discusses the American Headache Society (AHS) and American Academy of Neurology (AAN) guidelines for the treatment of acute setting.

5: SUDEP Rates Greater Than Previously Reported, Higher Among Nonwhite Children

Study data from the NIH/CDC Sudden Death in the Young (SDY) Case Registry suggest that nonwhite children and infants have rates of SUDEP mortality 1.5 times higher than whites.